BRIM ‐P: A phase I, open‐label, multicenter, dose‐escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation‐positive melanoma

ConclusionsA recommended and effective dose of vemurafenib for patients aged 12–17 years with metastatic or unresectable melanoma was not identified. Extremely low enrollment in this trial highlights the importance of considering the inclusion of adolescents with adult cancers in adult trials.

Source: Pediatric Blood and Cancer - January 19, 2018 Category: Cancer & Oncology Authors: Julia C. Chisholm, Jozef Suvada, Ira J. Dunkel, Michela Casanova, Weijiang Zhang, Natasha Ritchie, YounJeong Choi, Jane Park, Meghna Das Thakur, Stephen Simko, Nga Wan Rachel Tam, Andrea Ferrari Tags: RESEARCH ARTICLE Source Type: research